Muraglitazar: Beneficial or detrimental in the treatment of Type 2 diabetes?

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 9, 2006, Pages 1229-1233

  Doggrell, Sheila A ^a  

^a CHARLES DARWIN UNIVERSITY   (Australia)

Author keywords

High density lipoprotein cholesterol; Hyperglycaemia; Insulin sensitivity; Muraglitazar; PPAR ; PPAR ; Triglycerides; Type 2 diabetes

Indexed keywords

EZETIMIBE; FARGLITAZAR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MURAGLITAZAR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROBUCOL; RAGAGLITAZAR; TRIACYLGLYCEROL; TROGLITAZONE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETIC DIET; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLYCINE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; OXAZOLES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; WEIGHT GAIN;

EID: 33745434061     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.9.1229     Document Type: Article

References (9)

1. DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the Proactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled study. Lancet (2005) 366:1279-1289.
2. RUBINS HB, ROBINS SJ, COLLINS D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. (2002) 162:2597-2604.
3. DIABETES ATHEROSCLEROSIS INTERVENTION STUDY INVESTIGATORS: Effects of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (2001) 357:905-910.
4. BUSE JB, RUBIN CJ, FREDERICH R et al.: Muraglitazar, a dual (α /γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with Type 2 diabetes. Clin. Ther. (2005) 27:1181-1195.
5. NISSEN SE, WOLSKI K, TOPOL ER et al: Effect of muraglitazar on death and major adverse events in patients with Type 2 diabetes mellitus. JAMA (2005) 294:2581-2586.
6. DEVASTHALE PV, CHEN S, JEON Y et al.: Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N- 4-[2-(5-methyl-2-phenyl-4-oxazolyl) et hoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem. (2005) 48:2248-2250.
7. HARRITY T, FARRELLY D, TIEMAN A et al.: Muraglitazar, a novel (α /γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell function in db/ db mice. Diabetes (2006) 55:240-248.
8. SCHWARTZ S, RASKIN P, FONSECA V, GRAVELINE JF: Effect of troglitazone in insulin-treated patients with Type II diabetes mellitus. Troglitazone and exogenous insulin study group. N. Engl. J. Med. (1998) 338:861-866.
9. TENENBAUM A, MOTRO M, FISMAN EZ: Dual and pan-peroxisome proliferator-activate receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. (2005) 4:14.